Company type | Public |
---|---|
ISIN | US92556V1061 |
Industry | |
Predecessors | |
Founded | November 16, 2020 |
Headquarters | , U.S. |
Area served | Worldwide |
Key people |
|
Products | |
Revenue | US$15.39 billion (2023) |
US$766 million (2023) | |
US$54.7 million (2023) | |
Total assets | US$47.69 billion (2023) |
Total equity | US$20.47 billion (2022) |
Number of employees | c. 38,000 (2023) |
Subsidiaries |
|
Website | viatris |
Footnotes / references [1] |
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.[2]
The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community.[3][4]
Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue.[5]